Inspire Medical Systems, Inc.

Inspire Medical Systems (INSP) develops and commercialises an implantable neurostimulation therapy for obstructive sleep apnoea (OSA). Its Inspire device stimulates the hypoglossal nerve during sleep to reduce airway collapse, offering an alternative to continuous positive airway pressure (CPAP) for patients who struggle with that therapy. Investors should know the company’s prospects are tied to OSA diagnosis rates, physician adoption, reimbursement policies and ongoing clinical data supporting effectiveness and safety. Inspire benefits from intellectual property, a growing installed base and focused sales and training efforts, but it faces surgical adoption barriers, competitive technologies and regulatory or reimbursement shifts. As a medtech growth company with a market cap around $2.45bn, it may appeal to investors seeking exposure to durable healthcare needs; however, returns are not guaranteed and shares can be volatile. This is general information, not personalised advice — suitability depends on individual goals and risk tolerance.